A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

NCT04705090 | Unknown Phase 2 DMC

• 1 other identifier: YY-20394-010
• Study Type: interventional
• Target: 90
• Locations: 0 countries
• Sites: N/A

Brief Summary

A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T/NK cell lymphoma.

Conditions

PTCL

Outcome Measures

Primary Outcomes (1)

• ORR

  Objective Response Rate

  up to 12 months

Secondary Outcomes (5)

• DOR

  up to 12 months

• PFS

  up to 12 months

• DCR

  up to 12 months

• TTR

  up to 12 months

• Safety and Tolerability

  up to 12 months

Study Arms (1)

YY-20394 treatment

EXPERIMENTAL

YY-20394 tablets, 20mg spec, 80mg QD, 28 days for each cycle.

Drug: YY-20394 treatment

Interventions

YY-20394 treatment DRUG

Each treatment cycle is comprised of 28-day consecutive dosing of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if they are benefit from the treatment and the toxicity is tolerable.

YY-20394 treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and/or females over age 18.
• Histologically or cytologically confirmed diagnosis of relapsed or refractory peripheral T/NK cell lymphoma.
• Eastern Cooperative Oncology Group performance status of 0 to 1.
• Life expectancy of at least 3 months.
• At least one measurable lesion according to Lugano 2014.
• Adequate organ function.
• Had anti-tumor treatment within 2 weeks prior to the first dose of investigational product (including TKI, Chinese herbal anti-tumor treatment); within 4 weeks prior to the first dose of investigational product (including chemotherapy, radiotherapy, immunotherapy and major surgery); other targeted therapies with 5 half-life period prior to the first dose.
• Men and women of childbearing potential are willing to employ an effective method of contraception for the entire duration of study and 6 months after the last dose.
• Volunteers did not participate in other clinical trials within 1 month prior to study entry.
• Provision of signed and dated, written informed consent prior to any study- specific evaluation.

You may not qualify if:

• Previous treatment with any PI3K-delta inhibitors.
• Uncontrolled pleural effusion and ascites.
• The dosage of steroid hormone (prednisone equivalent) was greater than 20mg/day, and lasted for more than 14 days.
• Medical conditions in swallowing difficulty, malabsorption, or other chronic gastrointestinal disease that may hamper compliance and/ or absorption of the investigational agent.
• Drugs that may prolong the QT (such as anti-arrhythmic drugs) could not be interrupted during the study period.
• Evidence of central nervous system involvement of the malignancy, including invasion of brain parenchyma and meninges, or spinal cord compression.
• Have active viral, bacterial, fungal, or other infections that require systematic treatment (e.g., active tuberculosis), excluding nail bed fungal infections.
• Active infection with hepatitis B and C virus (volunteers with HBsAg or HBcAb positive but HBV-DNA negative, or HCV antibody positive but HCV-RNA negative can be enrolled).
• History of immune deficiency (acquired and congenital), or history of organ transplantation, or allogeneic bone marrow or hematopoietic stem cell transplantation; with active autoimmune disease or history of autoimmune disease (e.g., autoimmune enteritis and systemic lupus erythematosus).
• prior autologous hematopoietic stem cell transplantation within 90 days prior to the first dose of study drug.
• Presence of severe or uncontrolled cardiovascular disease.
• Medical history of active bleeding within 2 months prior to study entry, or currently achieved anticoagulant therapy, or susceptible to bleed by the judgement of investigator.
• Presence of concomitant diseases that are seriously endanger the safety of patient or affect the completion of the study by the investigator's judgment (e.g., uncontrolled hypertension, diabetes, thyroid diseases).
• Had received GCSF or blood transfusion treatment within 14 days prior to study entry.
• Female subjects of childbearing potential have a positive pregnancy test at the baseline.

Sponsors & Collaborators

• Shanghai YingLi Pharmaceutical Co. Ltd.: lead

Central Study Contacts

Hanying Bao, MD,PhD

CONTACT

86 21-51370693; hybao@yl-pharma.com

Yang Shu, MMeD

CONTACT

86 21-58320003; yshu@yl-pharma.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 8, 2021
• First Posted: January 12, 2021
• Study Start: April 1, 2021
• Primary Completion: December 1, 2022
• Study Completion: June 1, 2023
• Last Updated: January 12, 2021

Record last verified: 2020-12

Data Sharing

• IPD Sharing: Will not share